Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Project PragmaticaOncology Center of Excellence Project Pragmatica
  
  					Advancing evidence generation for approved oncology medical products
	
    Share
    Post
    Linkedin

    Email
    PrintImage
              pragmatica blueTraditional prospective randomized controlled trials in oncology are typically associated with significant monitoring, assessments, tests, and clinical follow up visits that can be burdensome to trial participants, investigators, and trial sponsors.

**Project Pragmatica**seeks to introduce functional efficiencies and enhance patient centricity by integrating aspects of clinical trials with real-world routine clinical practice through appropriate use of pragmatic design elements.

Pragmatic clinical trials may incorporate various design elements that are more reflective of routine clinical practice. Pragmatic trial elements take advantage of functional efficiencies such as fewer and simpler eligibility criteria and flexibilities in trial delivery and outcome measurement. The degree of flexibility is tailored to the trial context, keeping the safety of patients and the integrity of trial data at the forefront. This more "real-world" setting can reduce the burden of trial participation, with the hope to facilitate more diverse trial populations, more rapid enrollment, and reduced attrition. Pragmatic trials may have the potential to result in evidence that is more broadly representative of the general population affected by the clinical question.As part of a broader effort to modernize evidence generation, the FDA Oncology Center of Excellence launched Project Pragmatica in 2022 to explore the appropriate use of pragmatic design elements in trials for approved oncology medical products.

What is a randomized pragmatic clinical trial (PCT)?

A randomized pragmatic clinical trial is a type of clinical trial designed to compare an intervention and a comparator in participants who are more similar to those affected by the condition(s) under study in routine clinical practice settings. The intended purpose is to efficiently inform decision-making regarding the comparative balance of benefits, burdens, and risks of health interventions at the individual, community, or population level, and can integrate use of prospectively collected real-world data (RWD). Pragmatic clinical trials can impact multiple design elements, such as broader eligibility criteria, ease of recruitment and follow-up, flexibility in delivery of the intervention, and use more patient-centric outcomes (Califf et al). Along a continuum from explanatory to pragmatic, trials can be more or less pragmatic depending on the various elements that can be deployed to streamline procedures and data collection (Thorp et al).

**Project Pragmatica Objectives**

Explore the range of pragmatic elements that are feasible and appropriate to implement in cancer trials across a range of clinical and regulatory contexts while maintaining patient safety and data integrity.
	Collaborate with patients, trial investigators, pharmaceutical companies, government agencies and international healthcare policy stakeholders to evaluate opportunities and challenges in incorporating pragmatic elements into multiregional cancer trials.
	Foster research into evaluating potential benefits of pragmatic trial elements to patients, investigators and trial sponsors. (e.g., more rapid accrual, more heterogeneous population, less attrition, cost and time savings).Project Pragmatica leads include Drs. Donna Rivera, Harpreet Singh, and Paul Kluetz in addition to a multidisciplinary team of FDA scientists interested in efforts to make trials more efficient and patient-centric.

Additional OCE programs intersecting with Pragmatica include the Oncology Real World Evidence Program, Project Silver, Patient Focused Drug Development Program, Project Significant and Project Equity.

Interviews

Jungmeyer E. Pragmatic Approach to Trial Design Born from Lung-MAP Substudy IASLC Lung Cancer News. 21 March 2023.
	Ong M, Goldberg P. Conversation with The Cancer Letter: FDA’s Singh and Rivera describe the “new normal”—and the future—in cancer pragmatic trials The Cancer Letter, 9 December 2022; Vol. 48, No. 44.Questions:

For questions specifically on Project Pragmatica, please email: OCERWE@fda.hhs.gov
	For application-associated regulatory questions, please contact the relevant Office of Oncologic Diseases review division early and often to discuss innovative trial designs.

                                                                                  Content current as of:
      03/23/2023Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop